Sales data from Novartis's quarterly and annual reports

FDA-Approved Novartis's Kisqali Shows 28.5% Reduction in Early Breast Cancer Recurrence Risk

Sep 17, 2024, 05:12 PM

Novartis has announced that its breast cancer drug, Kisqali, has shown significant benefits in reducing the risk of recurrence in early breast cancer patients. A new analysis revealed that Kisqali reduces the risk of recurrence by 28.5% in a broad population of patients. The FDA has expanded the approval of Kisqali to include patients with earlier stages of the disease, providing tens of thousands of women access to a drug that could help prevent their cancer from returning. This approval is based on the efficacy and safety results of the NATALEE trial and includes patients with HR+/HER2- stage 2 & 3 breast cancer.